We are live on ! Find out more
AEGR

Aegerion Pharmaceuticals
AEGR

Delisted

AEGR was delisted on the 29th of November, 2016.

Back to rankings

58 hedge funds and large institutions have $84.5M invested in Aegerion Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 31 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

119% more capital invested

Capital invested by funds: $38.5M → $84.5M (+$46M)

78% more call options, than puts

Call options by funds: $1.26M | Put options by funds: $708K

18% less funds holding

Funds holding: 71 → 58 (-13)

61% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 31

81% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 16

Holders
58
Holders Change
-13
Holders Change %
-18.31%
% of All Funds
1.55%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
3
Increased
12
Reduced
31
Closed
16
Calls
$1.26M
Puts
$708K
Net Calls
+$553K
Net Calls Change
+$338K

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$853K
2
BC
Broadfin Capital
New York
+$608K
3
Renaissance Technologies
Renaissance Technologies
New York
+$601K
4
Citigroup
Citigroup
New York
+$93.5K
5
FMA
FNY Managed Accounts
New York
+$50.2K

Top Sellers

Rank Fund Capital Flow
1
KPF
K2 Principal Fund
Ontario, Canada
-$686K
2
SIM
Spark Investment Management
New York
-$476K
3
BIM
Bogle Investment Management
Massachusetts
-$382K
4
Federated Hermes
Federated Hermes
Pennsylvania
-$227K
5
Two Sigma Investments
Two Sigma Investments
New York
-$144K
Name Holding Trade Value Shares
Change 		Change in
Stake
AA
26
Ancora Advisors
Ohio
$217K -$5.68K -3,277 -4%
California Public Employees Retirement System
27
California Public Employees Retirement System
California
$190K -$7.8K -4,500 -7%
Citigroup
28
Citigroup
New York
$174K +$93.5K +53,968 +1,183%
FMA
29
FNY Managed Accounts
New York
$147K +$50.2K +28,972 +142%
BG
30
BlackRock Group
United Kingdom
$144K – – –
State Street
31
State Street
Massachusetts
$121K -$867 -500 -1%
Royal Bank of Canada
32
Royal Bank of Canada
Ontario, Canada
$108K -$31.2K -18,010 -33%
BlackRock
33
BlackRock
New York
$89K -$159 -92 -0.3%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$84K -$8.32K -4,804 -14%
Bank of America
35
Bank of America
North Carolina
$79K -$26.1K -15,088 -36%
Franklin Resources
36
Franklin Resources
California
$79K +$20.2K +11,664 +78%
Citadel Advisors
37
Citadel Advisors
Florida
$64K -$782 -451 -2%
ProShare Advisors
38
ProShare Advisors
Maryland
$55K -$5.8K -3,345 -15%
Two Sigma Advisers
39
Two Sigma Advisers
New York
$45K -$39K -22,500 -60%
Morgan Stanley
40
Morgan Stanley
New York
$44K -$63.5K -36,665 -71%
WAM
41
Wolverine Asset Management
Illinois
$39K – – –
GC
42
Guggenheim Capital
Illinois
$30K +$17.5K +10,124 New
Deutsche Bank
43
Deutsche Bank
Germany
$21K -$69.7K -40,199 -85%
Simplex Trading
44
Simplex Trading
Illinois
$20K +$10.4K +6,015 +747%
Walleye Trading
45
Walleye Trading
New York
$16K -$13.3K -7,700 -59%
BIM
46
BlackRock Investment Management
Delaware
$15K – – –
BA
47
BlackRock Advisors
Delaware
$14K -$2.06K -1,189 -21%
CG
48
Cutler Group
California
$13K +$1.73K +1,000 +27%
UBS Group
49
UBS Group
Switzerland
$11K -$12.2K -7,015 -65%
AG
50
Advisor Group
Arizona
$9K – – –
1
2
3

AEGR Hedge Fund Activity: Q3 2016 in Review

58 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aegerion Pharmaceuticals (AEGR) for Q3 2016, worth a combined $84.5M — up 119% from $38.5M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of AEGR and 3 opened new positions — a net loss of 13 holders — while 31 trimmed existing stakes and 12 added.

The largest buyer was Armistice Capital, adding an estimated $853K. The largest seller was K2 Principal Fund, cutting an estimated $686K.

  • 58 institutional investors held Aegerion Pharmaceuticals (AEGR) as of Q3 2016, down from 71 in Q2 2016.
  • Funds reported $84.5M of Aegerion Pharmaceuticals stock for Q3 2016, up 119% quarter-over-quarter.
  • 3 funds opened new Aegerion Pharmaceuticals positions in Q3 2016 and 16 closed out, a net change of -13 holders.
  • The largest Aegerion Pharmaceuticals buyer in Q3 2016 was Armistice Capital, an estimated $853K added.
  • The largest Aegerion Pharmaceuticals seller in Q3 2016 was K2 Principal Fund, an estimated $686K sold.

Based on aggregated 13F filings for Q3 2016.